Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tenofovir disoproxil + emtricitabine + rilpivirine
- Development stage
- Approved
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tenofovir disoproxil + emtricitabine + rilpivirine is a fixed-dose combination (FDC) antiretroviral medication used for the treatment of HIV-1 infection. Marketed under the brand names Complera and Eviplera, it was developed by Gilead Sciences in collaboration with Janssen Pharmaceutical. The regimen consists of three active ingredients: emtricitabine (a nucleoside reverse transcriptase inhibitor), rilpivirine (a non-nucleoside reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor). It is administered as a single tablet once daily with food. The drug is indicated as a complete regimen for treatment-naïve adults and pediatric patients (weighing at least 35 kg) with HIV-1 RNA levels ≤ 100,000 copies/mL, or as a replacement for stable regimens in virologically suppressed patients. It was first approved by the FDA in August 2011.
- Brand names
- CompleraEviplera
- Other names
- tenofovir disoproxil fumarate + emtricitabine + rilpivirineRPV/FTC/TDFTDF/FTC/RPVrilpivirine/emtricitabine/tenofovir disoproxil fumarate
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on tenofovir disoproxil + emtricitabine + rilpivirine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tenofovir disoproxil + emtricitabine + rilpivirine.